Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2015
Context: The Company announced its strategic goals and guidance for 2015, outlining plans for the advancement and commercialization of its RNAi therapeutics pipeline through 2020.
Key Financial Metrics
- Cash Position (Updated Guidance): The Company expects to end the year ended December 31, 2014, with approximately $880.0 million in cash.
- Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, profit, cash flow, or margins for the reporting period.
- Debt and Liquidity: Beyond the updated cash guidance, the filing text does not provide specific values for debt levels or other liquidity metrics.
Material Changes
The primary material change disclosed is the update to the cash guidance for the fiscal year ending December 31, 2014. The Company revised its expectation to end the year with approximately $880.0 million in cash. No other specific financial variances versus prior periods are detailed in this filing text.
Guidance, Outlook, and Risks
- 2015 Guidance: The Company provided goals and guidance for 2015 focused on advancing and commercializing its RNAi therapeutics pipeline.
- Long-term Outlook: Strategic plans were outlined for the period through 2020.
- Risks and Contingencies: The filing text does not explicitly detail specific risks or contingencies, though it notes that the information is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed 2015 operational goals and pipeline milestones.
- Confirm the updated cash balance of $880.0 million against the Company's most recent quarterly financial statements.
- Review subsequent filings for specific revenue and expense projections associated with the 2015 guidance.